Novo Nordisk steps up interest in diabetes stem cell therapies by Nick Paul Taylor Thursday, May 17, 2018 With the diabetes project moving to within a few years of the clinic, Novo is stepping up its interest in stem cell therapies more broadly.
Roivant licenses Ligand diabetes drug, founds Metavant by Nick Paul Taylor Wednesday, March 7, 2018 The midphase Type 2 diabetes candidate slots into the pipeline of Roivant’s newly minted cardiometabolic disease startup Metavant.
UnitedHealth puts Dexcom at center of diabetes management by Nick Paul Taylor Thursday, January 11, 2018 The initiative will provide certain UnitedHealth members with Dexcom’s CGM technology and personalized coaching to help manage their diabetes.
Metavention raises $65M to trial Type 2 diabetes treatment by Nick Paul Taylor Tuesday, January 9, 2018 The Minneapolis-based medtech firm is aiming to improve glucose control in diabetics by ablating nerves linked to metabolic organs.
Fractyl Labs ropes in $44M in series D funding by Emily Wasserman Friday, December 1, 2017 Fractyl plans to use the funds to develop its water-filled balloon device, Revita DMR.
News of Note—Attune Medical bags $10M; and more by Amirah Al Idrus Wednesday, October 18, 2017 Here's Wednesday's medtech news of note.
Merck pays $760M to buy into KalVista diabetes drug by Phil Taylor Tuesday, October 10, 2017 KalVista has been looking for a big pharma partner for its plasma kallikrein inhibitors, and just had its wish fulfilled by Merck & Co.
Lexicon builds case for Sanofi-partnered diabetes pill by Nick Paul Taylor Tuesday, August 15, 2017 Lexicon now has data from two phase 3 trials showing the effect of the SGLT1-SGLT2 inhibitor on A1C in patients with Type 1 diabetes is sustained over 52 weeks.
Roche taps Accenture to build diabetes analytics platform by Nick Paul Taylor Friday, July 28, 2017 Roche will build digital services on Accenture’s platform, enabling it to pull in and analyze data to improve the management of diabetes.
